AstraZeneca Plc reported positive results in two Phase 2b trials on 8 June for a candidate obesity and diabetes drug with potentially broad applications for cardiometabolic and kidney diseases. The drug, elecoglipron, is a small molecule GLP-1 receptor agonist that can be taken as a pill. It was in-licenced from Eccogene (Shanghai) Co Ltd in 2023 to be the backbone of AstraZeneca’s prospective treatments for obesity and weight-related diseases.
Abivax SA has confirmed plans to submit a new drug application for obefazimod, its candidate product for ulcerative colitis, to the US Food and Drug Administration late in the fourth quarter. This follows results from a Phase 3 trial that showed strong efficacy. The small molecule drug upregulates a microRNA known as miR124 in order to stabilise the immune response in patients with ulcerative colitis, a disease that affects the colon.
Les Laboratoires Servier SAS of France has extended its reach into the rare disease space with the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc of Boulder Colorado, US. The lead asset is sevasemten, a small molecule drug that is being developed for both Becker muscular dystrophy and Duchene muscular dystrophy. The two disorders are caused by mutations in the DMD gene which encodes for the dystrophin protein.
Following a European Commission announcement in March of a proposed new legal framework for start-up companies, Germany has reportedly lifted its opposition to giving more powers to an EU financial regulator – an important step towards creating a capital markets union. According to The Financial Times, the German finance minister Lars Klingbeil signalled his support for the centralised supervision of a unified capital market, which would effectively mean ceding powers from the German regulator to the European Securities and Markets Authority (ESMA), based in Paris.
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced funding for three experimental Bundibugyo ebolavirus vaccine candidates currently in preclinical development. Bundibugyo is the ebolavirus species responsible for the current outbreak in the Democratic Republic of Congo ad Uganda, but no licensed vaccine is currently available for this species, and none is in clinical development.
Eli Lilly and Co has announced plans to invest up to $3.83 billion to buy three companies developing candidate vaccines, effectively charting new territory in the field of infectious disease. Announced on 26 May, the acquisitions include Curevo Inc and Vaccine Company Inc of the US, and LimmaTech Biologics AG of Switzerland.
The World Health Organization has determined that the current outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda constitutes a public health emergency of international concern (PHEIC), but does not meet the criteria of a pandemic emergency. The determination was announced in a statement dated 17 May 2026.
Isomorphic Labs Ltd, with headquarters in London and global business offices in Lausanne, Switzerland and Cambridge, US, announced funding of $2.1 billion on 12 May, said to be the second largest equity funding round for a company since the start of the biotechnology industry. The Series B round comes only a year after the company raised $600 million for its activities, the company’s first external financing since its launch in 2021.
Bristol Myers Squibb Co has signalled a commitment to artificial intelligence with a strategic agreement with Anthropic PBC to deploy the AI tool Claude across the company’s research, clinical development, manufacturing, commercial and corporate functions. Announced on 20 May, the agreement will make the technology available to more than 30,000 BMS employees. The financial terms of the agreement were not disclosed.
A UK company with an ambition to develop a new class of therapeutics based on laboratory grown red blood cells has raised £3.2 million in seed funding. The financing was announced on 7 May and awarded to Scarlet Therapeutics Ltd which was founded by the University of Bristol, UK, professors Ash Toye and Jan Frayne. The company’s technology platform is based on engineered red blood cells with a potential for delivering therapeutic proteins in vivo to humans. The proteins remain inside the red blood cell membrane and therefore are not recognised by the immune system.